

Adaptive Strategies of Human Pathogenic Bacteria- Antibiotic Resistance, Host Immune Manipulation and Microbial Persistence Mechanisms

Doaa Ali Baaiw¹* Niran Adnan Aljoboury¹, Fatima A. Al-Hadidi¹

¹Department of Biology, College of Sciences, University of Kerbala, Karbala, Iraq

* doaa.ali@s.uokerbala.edu.iq

Received: 12 March (2026), Accepted: 29 March 2026. Published: 31 March 2026

ABSTRACT

Human pathogenic bacteria employ diverse strategies to survive antibiotics and host defenses. These adaptations contribute to chronic infections, treatment failures, and increased morbidity and mortality. This review explores three primary bacterial survival strategies antibiotic resistance, modulation of host immune responses, and microbial persistence. Antibiotic resistance arises through multiple genetic and biochemical mechanisms, including target modification, enzymatic inactivation, efflux pump overexpression, and horizontal gene transfer. Beyond resistance, pathogens actively manipulate host immune responses to evade detection, modulate immune signaling, and enhance colonization and dissemination. Additionally, microbial persistence mechanisms such as biofilm formation, phenotypic heterogeneity, and the emergence of persister cells allow bacteria to withstand antimicrobial treatments and immune-mediated clearance without acquiring permanent genetic resistance. These processes are not isolated; rather, they interact and reinforce each other, creating a complex network of survival strategies. Understanding these interconnected mechanisms is essential for designing more effective therapeutic approaches. By integrating insights from molecular microbiology, immunology, and clinical research, this review aims to provide a comprehensive framework for understanding bacterial adaptability. Such an integrated perspective can help identify potential targets for future antimicrobial and immunomodulatory therapies, ultimately improving the management of infections caused by multidrug-resistant and persistent bacterial pathogens.

Keywords: *Immune evasion, Antigenic variation, Selective pressures, Persister, Oxidative stress, Cytokine signaling, Biofilm formation*

Introduction

Antibiotic-resistant bacteria are a significant public health concern . Universal and careless administration of antibiotics, and the inherent flexibility of microbes has increased the rate of development of multidrug-resistant microorganisms, which is threatening the proper management of disease [1,2]. Bacteria have developed strategies to evade the host immune system and persist [3,4]. It is not only the resistance to antibiotics that determines the capacity of pathogenic bacteria to survive and multiply in the human host. Rather it is a dynamic and complex of adaptive mechanisms that allow bacteria to deal with environmental stressors, such as antimicrobial agents and host immune defense [5,6]. The bacteria are exposed to various adverse environments during infection i.e. nutrient limitation, oxidative stress, antimicrobial peptides, and killing by immune cells. The successful pathogens have been able to develop elaborate ways to detect these challenges, and to react in a manner that enhances their survival and continuity [7,8]. Traditionally, the bacterial adaptation studies have focused on antibiotic resistance. Nevertheless, there is a growing body of evidence that resistance is not a comprehensive explanation of the resistance and recurrence of most infections. Recent studies have focused on bacterial strategies, including immune manipulation and persistence. The strategies enable the bacteria to avoid immune surveillance, to regulate inflammatory reaction and to endure contact with the antibiotics without any irreversible genetic alterations [9,10]. The persistence in microbes such as biofilm formation or development of dormant or slow growing per sister cells is very vital in chronic and recurrent infections. These mechanisms allow the bacterial populations to cope with the killer conditions in the short run which lead to the treatment failure and extended disease courses. Notably, these persistence mechanisms tend to interact with an antibiotic resistance and immune evasion leading to a complicated system of survival mechanisms [11,12]. The purpose of the review is to absorb the existing information on the adaptive mechanisms of human pathogenic bacteria, especially antibiotic resistance and host immune manipulation and microbial persistence. Taking a comprehensive look at these processes, and not focusing on them separately, this review aims to

bring a better insight into the existence of bacteria in the host and to point out the possible directions to which more effective therapy and preventive strategies may evolve [13,14].

Overview of Human Pathogenic Bacteria and Selective Pressures

Bacteria face adverse environments during infection, including nutrient limitation, oxidative stress, and immune attack. These pathogens comprise Gram-positive and Gram-negative bacteria, obligate and facultative intracellular organisms and species with highly diverse metabolic flexibility and virulence potential [15,16]. Nevertheless, irrespective of such diversity, one common attribute to all successful human pathogens is their capacity to respond to selective forces both in-vitro and in-vivo within a short time frame [17,18].

The pathogenic bacteria are subjected to selective pressures that occur in different sources. Bacteria in the human host are confronted with difficult challenges posed by natural and adaptive immune responses [19,20]. These are physical barriers which are the epithelial surfaces, chemical defenses like antimicrobial peptides and cellular defenses which include phagocytosis, oxidative burst and cytokine mediated inflammation. Only when they are able to fill a nutrient niche will exogenous bacteria be able to invade the intestine. Through a variety of strategies, including food competition, the healthy gut microbiota completely occupies these niches and stops pathogen intestinal invasion [21,22]. In order to endure such environmental conditions, pathogens have also evolved ways of detecting environmental signals and varying gene expression, which enables them to adjust metabolism, virulence and stress response pathways (figure1) [23,24].




Figure 1. Selective pressures influencing the evolution of human pathogenic bacteria in the host environment. (A) Host-imposed selective pressures during infection, such as innate and adaptive immune responses, nutrient constraints, oxidative stress and competition with the host microbiota. (B) Pressures in treatment and stress, especially exposure to antibiotics, which induce bacterial stress reactions, tolerance, and development of adaptive mechanisms of survival.

Other than the host, anthropogenic pressures are the important factors that influence bacterial evolution. The intensive application of antibiotics in the clinical medicine, agriculture, and animal husbandry sectors has resulted in formidable selective pressure in favor of resistant and tolerant bacterial communities [25]. The selection of adaptive characteristics that increase survival in the absence of conferring classical resistance, especially in response to exposure to sub-lethal concentrations of antibiotics, is facilitated by exposure to sub-lethal concentrations of antibiotics. These external forces are frequently associated with genetic diversification by mutation and horizontal gene transfer which allow the rapid transfer of adaptive phenotypes among bacterial communities [26,27]. Notably, selective pressures do not work independently but will dynamically interact throughout the process of infection. As an example, immune stress can cause bacterial stress responses, which both increase antibiotic tolerance and antibiotic exposure can change bacterial surface structures in a manner that influences immune recognition. This network of selective pressures gives rise to the complex adaptive phenotypes such as

immune evasion, persistence and resistance [28,29]. It is necessary to comprehend the nature and origins of such selective pressures to understand its mode of adaptive strategies in the following sections. It gives us a conceptual model of valuing the integration of environmental cues by pathogenic bacteria to maximize survival, colonization and prolonged persistence in the human host (figure 2) [30,31].




Figure 2. Integrated host–pathogen interactions driving bacterial survival and adaptation.

Antibiotic Resistance Mechanisms in Pathogenic Bacteria

Antibiotic resistance involves target modification, enzymatic inactivation, efflux pump overexpression, and horizontal gene transfer [32]. Summarizes the major antibiotic resistance mechanisms employed by human pathogenic bacteria (Table1) [33]. One of the primary effects of the intense selection pressure brought about by the widespread use of antibiotics in the clinical, agricultural, and environmental settings is the emergence of resistance mechanisms. Even in the presence of antimicrobial treatments that seek to eradicate them, these activities aid in the survival, growth, and multiplication of bacteria [34]. Alteration of antibiotic targets is one of the most frequently used resistance mechanisms in which mutation or enzymatic changes cause a loss of drug binding affinity. They include changes in penicillin-binding proteins in -lactam resistance, and changes in ribosomal changes which cause macrolide and aminoglycoside

resistance[35,36]. The other predominant process is enzymatic deactivation of antibiotics, including the formation of β -lactamases that dismantle β -lactam antibiotics, making them inactive. The β -lactamases with extended spectra [ESBLs] and carbapenems are particularly dangerous because they are widespread in terms of their activity towards last-resort antibiotics [37]. Another method that bacteria use to evade antibiotics is the active expression of efflux pumps through which the bacterium can physically remove antibiotics in the cell and reduce the drug concentration to non-lethal levels. These pumps are either a highly specific pump or multidrug in nature, which may lead to cross resistance to various classes of antibiotics. Further, decreased membrane permeability, and especially in Gram-negative bacteria, restricts entry of antibiotics by altering porins and outer membrane proteins [38,39]. One of the main reasons that have increased the rate of resistance spread is horizontal gene transfer which enables a resistance determinant to propagate fast through plasmids, transposons and integrons. This procedure helps the development of the multidrug-resistant strains and makes the work of the infection control more complicated. Notably, antibiotic resistance is frequently accompanied with other adaptive behaviors such as immune avoidance and persistence, which point to their combination in a larger survival strategy but not as a singular phenomenon [40,41].

Table 1. Major antibiotic resistance mechanisms in human pathogenic bacteria

Resistance mechanism	Description	Representative examples
Target modification	Structural alteration of antibiotic targets	Altered PBPs in <i>Streptococcus pneumoniae</i>
Enzymatic inactivation	Enzymes degrade or modify antibiotics	β -lactamases in <i>Escherichia coli</i>
Efflux pumps	Active removal of antibiotics from the cell	AcrAB-TolC in Gram-negative bacteria
Reduced permeability	Decreased antibiotic uptake	Porin loss in <i>Pseudomonas aeruginosa</i>
Horizontal gene transfer	Spread of resistance genes between bacteria	Plasmid-mediated carbapenemases

Bacterial Strategies for Host Immune System Manipulation

Pathogens also manipulate host immune responses to evade detection and enhance colonization. The host immune system controls bacterial infections but can also contribute to tissue damage. Bacteria can manipulate the host immune response to promote survival. The host immune system recognizes bacterial pathogens through immune cell activation [42,43]. Bacteria evade the host immune system by producing immune evasion proteins. Other pathogens also produce proteins that block the activation of complement that inhibit opsonization and phagocytosis (Table 2) [44,45]. Pathogenic bacteria can actively suppress or regulate the immune responses by disrupting the activity of cytokines signaling and immune cells. As an example, some bacteria inject effector proteins into cells of the host by specific secretion systems, and cause interference with intracellular signaling cascades that respond to inflammation and antimicrobial activity. By producing anti-inflammatory cytokines or immune cell death, numerous pathogenic bacteria control host immunity, fostering an environment that is favorable to their survival. [46,47]. Intracellular pathogens survive inside host cells, such as macrophages and epithelial cells, avoiding antibodies and antibiotics. These bacteria can change the maturation of the phagosomes or oxidative killing, which makes the immune cells protective niches. Notably, the immune manipulation tends to increase the bacterial persistence and the chronic infection, which is part of the recurrence and chronic colonization [48,49]. Host-pathogen interactions are complicated by the interplay between immune evasion and other adaptive mechanisms, including antibiotic resistance and persistence. These mechanisms of immune manipulation would help in understanding how to devise therapies that would reestablish a proper immune response and supplement antimicrobial therapy [50].

Table 2. Key mechanisms of immune system manipulation by pathogenic bacteria

Immune manipulation strategy	Mode of action	Representative pathogens
Antigenic variation	Alters surface antigens to evade recognition	<i>Neisseria gonorrhoeae</i>
Capsule formation	Prevents phagocytosis	<i>Streptococcus pneumoniae</i>
Complement inhibition	Blocks complement-mediated killing	<i>Staphylococcus aureus</i>
Secretion of effector proteins	Disrupts host immune signaling	<i>Salmonella enterica</i>
Intracellular survival	Avoids immune clearance within host cells	<i>Mycobacterium tuberculosis</i>

Microbial Persistence and Survival Mechanisms

Microbial persistence mechanisms, including biofilm formation and persister cells, help bacteria withstand treatments. Bacteria can survive in the host environment by forming biofilms and producing virulence factors that aid colonization. These processes are prominent in chronic, recurrent and treatment-refractory infections [51]. One of the most well-defined persistence mechanisms is biofilm formation, in which bacterial cells embed themselves in an extracellular matrix composed of proteins, polysaccharides, and extracellular DNA. In addition to creating micro habitats with minimal nutrition supply and oxygen gradient, biofilms provide physical resistance to immune effector molecules and antibiotics. Since most antimicrobial drugs target cell divisions in active growth, these conditions promote slack growth or dormancy, rendering most antibiotics ineffective [52,53]. The other significant persistence strategy is that of the formation of persister cells which is a small minority of dormant or metabolically inactive cells capable of enduring lethal antibiotic concentration. Persister cells are genetically identical to other members of the bacterial population but have transient tolerance, which has been attributed to changed states of metabolism and stress-response. These cells are capable of resuscitation and repopulation upon the removal of the antibiotic pressure, hence causing infection relapse [54,55].

Stress response pathways that are used by pathogenic bacteria to acclimatize to nutrient limitation, oxidative stress, and immune attack include toxin-antitoxin systems and stringent response signaling. These control systems enable bacteria to promptly shift to survival where growth goes into the background. Notably, the mechanism of persistence can persist along with antibiotic resistance and immune evasion causing overlapping defense measures that improve long-term survival in the host [56,57]. The concept of microbial persistence plays a critical role in treating chronic infections due to the inability of traditional antibiotic treatment to kill the enduring bacterial communities. Attack on the persistence-related mechanisms can be thus a promising approach to enhancing treatment outcomes [58]. Tolerance is the ability of a whole bacterial population to withstand extended treatment to a bactericidal antibiotic without the minimum inhibitory concentration (MIC) changing is known as tolerance. Tolerant cells do not proliferate during treatment, but they need to be exposed for a longer period of time in order to be destroyed (i.e., a greater minimum duration for death[59]. Persistence Only a tiny subset of bacteria, known as persister cells, can withstand high antibiotic concentrations in persistence, a particular type of tolerance that produces a biphasic death curve (rapid murder of most cells + slow survival of persisters). These survivors can regenerate after the antibiotic is stopped and are phenotypically tolerant but do not exhibit an elevated MIC [60]. The HipBA and MazEF systems are two examples of toxin-antitoxin (TA) systems, which are important for bacterial persistence. In *Escherichia coli*, the MazEF system promotes growth arrest and programmed cell death in response to environmental stress, whereas the HipBA system controls the development of persister cells under antibiotic treatment [61].

Interconnection Between Resistance, Immune Evasion, and Persistence

Emerging evidence indicates that antibiotic resistance, immune evasion, and microbial persistence are not independent adaptive strategies, but rather interconnected processes that function as an integrated survival network. Pathogenic bacteria coordinate these mechanisms to enhance their ability to withstand both antimicrobial therapy and host immune defenses [62,63]. Antibiotic exposure plays a central role in this interplay. Sub-inhibitory concentrations of antibiotics can modulate bacterial gene expression, leading to alterations in surface antigens, virulence factors, and biofilm formation. These changes reduce immune recognition and promote

www.zjhms.alzahraa.edu.iq

persistent infections. Conversely, immune-mediated stresses—such as reactive oxygen species and antimicrobial peptides—can induce bacterial stress responses that enhance antibiotic tolerance [64,65]. Resistance and persistence are also closely linked at the metabolic level. Resistance mechanisms may reduce the metabolic burden imposed by antibiotics, enabling bacteria to allocate resources toward survival rather than rapid growth. In parallel, persistence prolongs bacterial survival under antibiotic pressure, increasing the likelihood of acquiring resistance through mutations or horizontal gene transfer [66,67]. Immune evasion further strengthens this adaptive network by allowing bacterial subpopulations to escape clearance. Intracellular survival is a key example, as bacteria residing within host cells are protected from both immune attack and antibiotic exposure. These intracellular niches can support the development of specialized phenotypes, such as small colony variants, which enhance survival under hostile conditions and contribute to recurrent and persistent infections [68–69]. The *pmrA/pmrB* operon in Gram-negative bacteria is a well-studied illustration of this molecular interaction. When this system is activated, lipid A undergoes changes such the addition of phosphoethanolamine or L-Ara4N. These modifications lower the outer membrane's negative charge, which reduces polymyxin binding and confers antibiotic resistance while also hindering TLR4-mediated immune detection and encouraging immune evasion [70]. Importantly, despite seeming *in vitro* susceptibility, bacteria in biofilms or persister states can withstand antibiotic treatment without developing genetic resistance, which frequently results in treatment failure and illness recurrence. This demonstrates the shortcomings of existing diagnostic techniques and emphasizes the necessity of standardized procedures that can identify these phenotypes [71]. Therapeutic approaches that focus on a particular pathway are unlikely to be successful due to the interconnectedness of various systems. Combination techniques, on the other hand, have more potential to improve treatment outcomes and limit pathogen adaptation within the host by concurrently disrupting numerous bacterial activities, such as metabolic pathways, resistance mechanisms, and immune evasion strategies [72–73].

Conclusion and Future Perspectives

Bacteria that pose a danger to humans have an impressive adaptation potential, and thus they can stay alive and reproduce under heavy selection pressure associated with antimicrobial treatment and the immune system of a human host. The current review also outlines that antibiotic

www.zjhms.alzahraa.edu.iq

resistance, manipulation of the host immune, and microbial persistence all play a role in bacterial survival, chronicity of diseases and treatment failure. These, adaptive strategies are not phenomena that appear in isolation but rather related processes that support each other and make it more difficult to handle infections. The molecular connections between resistance, immune evasion and persistence should be unraveled in future studies in order to find areas of vulnerability that can be utilized as a point of therapy. New antimicrobials, anti-virulence agents, and immunomodulatory therapies are developing and will have a role to play especially in combination with methods to address biofilms and persister cells. Besides, better antibiotic stewardship and infection control practices are also necessary to minimize the selective pressure and the transmission of adaptive bacterial characteristics. An in-depth insight into bacterial adaptability will play a very significant role in solving the increasing threat of persistent and resistant infections on the global front. Novel therapies are needed to improve public health and reduce infectious disease burden.

Acknowledgment

The authors gratefully acknowledgment the support and guidance provided by the Department of Biology, University of Kerbala, which greatly contributed to the completion of the study

References:

1. Grant, S.S. and Hung, D.T., (2013). Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response. *Virulence*, 4(4), pp.273–283. DOI: 10.4161/viru.23987.
2. Belkaid, Y. and Hand, T.W., (2014). Role of the microbiota in immunity and inflammation. *Cell*, 157(1), pp.121–141. DOI: 10.1016/j.cell.2014.03.011.
3. Price, L.B., Hungate, B.A., Koch, B.J., Davis, G.S. and Liu, C.M., (2017). Colonizing opportunistic pathogens (COPs): the beasts in all of us. *PLoS Pathogens*, 13(8), p.e1006369. DOI 10.1371/journal.ppat.1006369.
4. Bellini, W.J., Rota, J.S., Lowe, L.E., Katz, R.S., Dyken, P.R., Zaki, S.R., Rota, P.A., (2005). Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. *The Journal of Infectious Diseases*, 192(10), pp. 1686–1693. DOI: 10.1086/497169.
5. Kaufmann, S.H.E., (2011). Intracellular pathogens: living in an extreme environment. *Immunological Reviews*, 240(1), pp.5–10. DOI: 10.1111/j.1600-065X.2010.01001.x

6. Cossart, P. and Helenius, A.,(2014) . Endocytosis of viruses and bacteria. *Cold Spring Harbor perspectives in biology*, 6(8), p.a016972 DOI: 10.1101/cshperspect.a016972.
7. Foley, J., (2015). Mini-review: strategies for variation and evolution of bacterial antigens. *Computational and Structural Biotechnology Journal*, 13, pp.407–416. doi: 10.1016/j.csbj.2015.07.002.
8. Iwasaki, A. and Medzhitov, R., (2015). Control of adaptive immunity by the innate immune system. *Nature Immunology*, 16(4), pp.343–353. DOI: 10.1038/ni.3123.
9. Schenten, D. and Medzhitov, R.,(2011). The control of adaptive immune responses by the innate immune system. *Advances in Immunology*, 109, pp. 87–124. DOI: 10.1016/B978-0-12-387664-5.00003-0.
10. Netea, M.G., Joosten, L.A., Latz, E., Mills, K.H., Natoli, G., Stunnenberg, H.G. and Xavier, R.J., (2016). Trained immunity: a program of innate immune memory in health and disease. *Science*, 352(6284), p.aaf1098 doi: 10.1126/science.aaf1098.
11. Netea, M.G., Quintin, J. and van der Meer, J.W.M., (2011). Trained immunity: a memory for innate host defense. *Cell Host & Microbe*, 9(5), pp. 355–361. DOI: 10.1016/j.chom.2011.04.006.
12. Lerm, M. and Netea, M.G., (2016). Trained immunity: a new avenue for tuberculosis vaccine development. *Journal of Internal Medicine*, 279(4),pp. 337–346. DOI: 10.1016/j.chom.2011.04.00.
13. Sánchez-Ramón, S., Conejero, L., Netea, M.G., Sancho, D., Palomares, Ó. and Subiza, J.L., (2018) . Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. *Frontiers in immunology*, 9, p. 2936. DOI: 10.3389/fimmu.2018.02936.
14. Arts, R.J., Joosten, L.A. and Netea, M.G.,(2018) . The potential role of trained immunity in autoimmune and autoinflammatory disorders. *Frontiers in immunology*, 9, p.298. DOI: 10.3389/fimmu.2018.00298.
15. Zhu, Y., Yao, S. and Chen, L.,(2011) . Cell surface signaling molecules in the control of immune responses: a tide model. *Immunity*, 34(4), pp. 466-478. DOI: 10.1016/j.immuni.2011.04.008.

16. Cooper, A.M., Dalton, D.K., Stewart, T.A., Griffin, J.P., Russell, D.G. and Orme, I.M., (1993). Disseminated tuberculosis in interferon gamma gene-disrupted mice. *The Journal of experimental medicine*, 178(6),pp. 2243-2247 DOI: 10.1084/jem.178.6.2243.
17. Jupelli, M., Selby, D.M., Guentzel, M.N., Chambers, J.P., Forsthuber, T.G., Zhong, G., Murthy, A.K. and Arulanandam, B.P., (2010) . The contribution of interleukin-12/interferon- γ axis in protection against neonatal pulmonary Chlamydia muridarum challenge. *Journal of interferon & cytokine research*, 30(6), pp. 407-415 DOI: 10.1089/jir.2009.0083.
18. McCall, M.B. and Sauerwein, R.W., (2010) . Interferon- γ —central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. *Journal of leukocyte biology*, 88(6), pp. 1131-1143. DOI: 10.1189/jlb.0310137.
19. Elkins, K.L., Colombini, S.M., Meierovics, A.I., Chu, M.C., Chou, A.Y. and Cowley, S.C.,(2010) . Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma. *Microbes and infection*, 12(1), pp. 28-36. DOI: 10.1016/j.micinf.2009.09.012.
20. Kima, P.E. and Soong, L., (2013). Interferon gamma in leishmaniasis. *Frontiers in immunology*, 4, p. 156. DOI: 10.3389/fimmu.2013.00156.
21. Walker, D.H. and Dumler, J.S.,(2015), May. The role of CD8 T lymphocytes in rickettsial infections. In *Seminars in immunopathology*, 37(3), 289-299). Berlin/Heidelberg: Springer Berlin Heidelberg. doi:10.1007/s00281-015-0480-x .
22. Horrocks, V., King, O.G., Yip, A.Y., Marques, I.M. and McDonald, J.A.,(2023). Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization. *Microbiology*, 169(8), p. 001377. DOI 10.1099/mic.0.001377.
23. Baishya, J. and Wakeman, C.A., (2019). Selective pressures during chronic infection drive microbial competition and cooperation. *npj Biofilms and Microbiomes*, 5(1), p.16. ; <https://doi.org/10.1038/s41522-019-0089-2>.
24. Malek, G.K., Hussein, S.A.M. and Mohammed, A.A.,(2024). Effect of Puberty and Gender on Metabolic Hormones Level and Lipid Profile in Patients with Growth Hormone Deficiency. *International Journal of Medical Science and Dental Health*, 11(11), pp.63-72. Doi: <https://doi.org/10.55640/ijmsdh-11-11-06>.

25. Sonje, M.B., Abram, M., Stenzel, W. and Deckert, M.,(2010). *Listeria monocytogenes* (delta-actA mutant) infection in tumor necrosis factor receptor p55-deficient neonatal mice. *Microbial pathogenesis*, 49(4), pp. 186-195. doi:10.1016/j.micpath.2010.05.012.
26. Mohammed, A. A., Mahmoud, H. Q., Daham, R. I., Yaseen, O. Q., Sardal, M. H., Jasim, B. H., & Mohammed, K. R. (2025). Biochemical and Neuroendocrine Markers of Academic Stress in Iraqi Postgraduate Students: A Narrative Review. *International Journal of Body, Mind & Culture* (2345-5802), 12(8) 8, pp. 14-26. DOI: 10.61838/ijbmc.v12i8.1054.
27. Sergerie, Y., Rivest, S. and Boivin, G., (2007). Tumor necrosis factor- α and interleukin-1 β play a critical role in the resistance against lethal herpes simplex virus encephalitis. *Journal of Infectious Diseases*, 196(6), pp. 853 860. <https://doi.org/10.1086/520094>.
28. Miura, Y., Misawa, N., Kawano, Y., Okada, H., Inagaki, Y., Yamamoto, N., Ito, M., Yagita, H., Okumura, K., Mizusawa, H. and Koyanagi, Y., (2003). Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. *Proceedings of the National Academy of Sciences*, 100(5), pp. 2777-2782. **DOI:** 10.1073/pnas.0438019100.
29. Allie, N., Grivennikov, S.I., Keeton, R., Hsu, N.J., Bourigault, M.L., Court, N., Fremond, C., Yermeev, V., Shebzukhov, Y., Ryffel, B. and Nedospasov, S.A., (2013). Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection. *Scientific reports*, 3(1), p. 1809. **DOI:** 10.1038/srep01809.
30. Martínez-Barricarte, R., Markle, J.G., Ma, C.S., Deenick, E.K., Ramírez-Alejo, N., Mele, F., Latorre, D., Mahdavian, S.A., Aytakin, C., Mansouri, D. and Bryant, V.L., (2018). Human IFN- γ immunity to mycobacteria is governed by both IL-12 and IL-23. *Science immunology*, 3(30), p. eaau6759. **DOI:** 10.1126/sciimmunol.aau6759.
31. Awoniyi, M., Miller, S.I., Wilson, C.B., Hajjar, A.M. and Smith, K.D.,(2012). Homeostatic regulation of Salmonella-induced mucosal inflammation and injury by IL-23. *PLoS One*, 7(5), p. e37311. DOI: 10.1371/journal.pone.0037311.
32. Henry, C.J., Grayson, J.M., Brzoza-Lewis, K.L., Mitchell, L.M., Westcott, M.M., Cook, A.S. and Hiltbold, E.M., (2010). The roles of IL-12 and IL-23 in CD8+ T cell-mediated immunity against *Listeria monocytogenes*: insights from a DC vaccination model. *Cellular Immunology*, 264(1),pp. 23-31.DOI: 10.1016/j.cellimm.2010.04.007.

33. Schneider, B.E., Korbel, D., Hagens, K., Koch, M., Raupach, B., Enders, J., Kaufmann, S.H., Mittrücker, H.W. and Schaible, U.E., (2010). A role for IL-18 in protective immunity against *Mycobacterium tuberculosis*. *European journal of immunology*, 40(2), pp. 396-405. DOI: 10.1002/eji.200939583.
34. Reygaert, W.C., (2018). Antibiotic resistance: Current perspectives. *ACS Omega*, 3(7), pp. 6959–6969. Available at: <https://doi.org/10.1021/acsomega.7b01368>.
35. Oliveira, A.C., Gomes-Neto, J.F., Barbosa, C.H.D., Granato, A., Reis, B.S., Santos, B.M., Fucs, R., Canto, F.B., Nakaya, H.I., Nobrega, A. and Bellio, M., (2017). Crucial role for T cell-intrinsic IL-18R-MyD88 signaling in cognate immune response to intracellular parasite infection. *Elife*, 6, p. e30883. DOI: <https://doi.org/10.7554/eLife.30883.001>.
36. Pham, O.H., O'Donnell, H., Al-Shamkhani, A., Kerrinnes, T., Tsolis, R.M. and McSorley, S.J., (2017). T cell expression of IL-18R and DR3 is essential for non-cognate stimulation of Th1 cells and optimal clearance of intracellular bacteria. *PLoS pathogens*, 13(8), p. e1006566. <https://doi.org/10.1371/journal.ppat.1006566>.
37. Nadaf, N.H., Mohammed, A.A. and Nadaf, S.H., (2025). Inspiration from Natural Biomass Utilization System for a Sustainable Lignocellulosic Refinery. In *Recent Trends in Lignocellulosic Biofuels and Bioenergy: Advancements and Sustainability Assessment*, pp. 123-141. Singapore: Springer Nature Singapore. 10.1007/978-981-96-4636-45 .
38. Khader, S.A., Pearl, J.E., Sakamoto, K., Gilmartin, L., Bell, G.K., Jelley-Gibbs, D.M., Ghilardi, N., DeSavage, F. and Cooper, A.M., (2005). IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN- γ responses if IL-12p70 is available. *The Journal of Immunology*, 175(2), pp. 788-795. DOI: 10.4049/jimmunol.175.2.788.
39. Umemura, M., Yahagi, A., Hamada, S., Begum, M.D., Watanabe, H., Kawakami, K., Suda, T., Sudo, K., Nakae, S., Iwakura, Y. and Matsuzaki, G., (2007). IL-17-mediated regulation of innate and acquired immune response against pulmonary *Mycobacterium bovis* bacille Calmette-Guerin infection. *The Journal of Immunology*, 178(6), pp. 3786-3796. <https://doi.org/10.4049/jimmunol.178.6.3786>.
40. Bai, H., Cheng, J., Gao, X., Joyee, A.G., Fan, Y., Wang, S., Jiao, L., Yao, Z. and Yang, X., (2009). IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial

- infection through modulating dendritic cell function. *The journal of immunology*, 183(9), pp. 5886-5895.. <https://doi.org/10.4049/jimmunol.0901584>.
41. Wozniak, T.M., Saunders, B.M., Ryan, A.A. and Britton, W.J., (2010). Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. *Infection and immunity*, 78(10), pp. 4187-4194 <https://doi.org/10.1128/IAI.01392-09> .
 42. Roberts, L.M., Davies, J.S., Sempowski, G.D. and Frelinger, J.A.,(2014). IFN- γ , but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection. *Vaccine*, 32(29), pp. 3595-3603. doi:10.1016/j.vaccine.2014.05.013.
 43. Feinen, B., Jerse, A.E., Gaffen, S.L. and Russell, M.W., (2010). Critical role of Th17 responses in a murine model of Neisseria gonorrhoeae genital infection. *Mucosal immunology*, 3(3), pp. 312-321. <https://doi.org/10.1038/mi.2009.139>.
 44. Wang, X., Chan, C., Yang, M., Deng, J., Poon, V.K., Leung, V.H., Ko, K.H., Zhou, J., Yung Yuen, K., Zheng, B.J. and Lu, L., (2011). A critical role of IL-17 in modulating the B-cell response during H5N1 influenza virus infection. *Cellular & molecular immunology*, 8(6), pp. 462-468. doi:10.1038/cmi.2011.
 45. Kelly, M.N., Kolls, J.K., Happel, K., Schwartzman, J.D., Schwarzenberger, P., Combe, C., Moretto, M. and Khan, I.A., (2005). Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. *Infection and immunity*, 73(1), pp. 617-621. doi:10.1128/IAI.73.1.617-621.2005.
 46. Tosello Boari, J., Amezcua Vesely, M.C., Bermejo, D.A., Ramello, M.C., Montes, C.L., Cejas, H., Gruppi, A. and Acosta Rodríguez, E.V.,(2012). IL-17RA signaling reduces inflammation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils. *PLoS pathogens*, 8(4),p. e1002658. <https://doi.org/10.1371/journal.ppat.1002658>.
 47. Pandey, S., Kant, S., Khawary, M. and Tripathi, D., (2022). Macrophages in microbial pathogenesis: commonalities of defense evasion mechanisms. *Infection and Immunity*, 90(5), p. e00291-21. <https://doi.org/10.1128/iai.00291-21>.
 48. Findlay, E.G., Greig, R., Stumhofer, J.S., Hafalla, J.C., De Souza, J.B., Saris, C.J., Hunter, C.A., Riley, E.M. and Couper, K.N.,(2010). Essential role for IL-27 receptor signaling in

- prevention of Th1-mediated immunopathology during malaria infection. *The Journal of Immunology*, 185(4), pp. 2482-2492. **DOI:** 10.4049/jimmunol.0904019.
- 49.** Rosas, L.E., Keiser, T., Pyles, R., Durbin, J. & Satoskar, A.R. (2003) ‘Development of protective immunity against cutaneous leishmaniasis is dependent on STAT1-mediated IFN signaling pathway’, *European Journal of Immunology*, 33(7), pp. 1799–1805. **DOI: 10.1002/eji.200323163.**
- 50.** Khader, S.A., Guglani, L., Rangel-Moreno, J., Gopal, R., Fallert Junecko, B.A., Fountain, J.J., Martino, C., Pearl, J.E., Tighe, M., Lin, Y.Y. and Slight, S., (2011). IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. *The Journal of Immunology*, 187(10), pp. 5402-5407. **DOI:** 10.4049/jimmunol.1101377.
- 51.** Meeks, K.D., Sieve, A.N., Kolls, J.K., Ghilardi, N. and Berg, R.E., (2009). IL-23 is required for protection against systemic infection with *Listeria monocytogenes*. *The Journal of Immunology*, 183(12), pp. 8026-8034. **DOI:** 10.4049/jimmunol.0901588.
- 52.** Markel, G., Bar-Haim, E., Zahavy, E., Cohen, H., Cohen, O., Shafferman, A. and Velan, B., (2010). The involvement of IL-17A in the murine response to sub-lethal inhalational infection with *Francisella tularensis*. *PLoS one*, 5(6), p.e11176. **DOI:** 10.1371/journal.pone.0011176 .
- 53.** Cook, K.D., Shpargel, K.B., Starmer, J., Whitfield-Larry, F., Conley, B., Allard, D.E., Rager, J.E., Fry, R.C., Davenport, M.L., Magnuson, T. and Whitmire, J.K., (2015). T follicular helper cell-dependent clearance of a persistent virus infection requires T cell expression of the histone demethylase UTX. *Immunity*, 43(4), pp.703-714. **DOI:** 10.1016/j.immuni.2015.09.002.
- 54.** Wang, X., Dong, Q., Li, Q., Li, Y., Zhao, D., Sun, J., Fu, J., Meng, F., Lin, H., Luan, J. and Liu, B., (2018). Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients. *Gastroenterology*, 154(8), pp. 2222-2236. **DOI:** 10.1053/j.gastro.2018.03.021.
- 55.** Moretto, M.M., Hwang, S. and Khan, I.A., (2017). Downregulated IL-21 response and T follicular helper cell exhaustion correlate with compromised CD8 T cell immunity during chronic toxoplasmosis. *Frontiers in immunology*, 8, p. 1436. **DOI:** 10.3389/fimmu.2017.01436.

- 56.** Eto, D., Lao, C., DiToro, D., Barnett, B., Escobar, T.C., Kageyama, R., Yusuf, I. and Crotty, S.,(2011). IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. *PLoS one*, 6(3), p.e17739. **DOI:** 10.1371/journal.pone.0017739.
- 57.** Aherkar, V.V., Mohammed, A.A., Al-Shimary, A.A., Kshirsagar, V., Shendage, R., Ubale, P.A., Bhairunagi, S.B. and Ovhal, R.M.,(2025). Photocatalytic dye degradation efficacy and antimicrobial potency of zinc oxide nanoparticles synthesized via sol-gel method. *Next Materials*, 9, p. 100972. DOI:10.1016/j.nxmate.2025.100972.
- 58.** Bunn, P.T., Montes de Oca, M., de Labastida Rivera, F., Kumar, R., Ng, S.S., Edwards, C.L., Faleiro, R.J., Sheel, M., Amante, F.H., Frame, T.C. and Muller, W., (2018). Distinct roles for CD4⁺ Foxp3⁺ regulatory T cells and IL-10-mediated immunoregulatory mechanisms during experimental visceral Leishmaniasis caused by *Leishmania donovani*. *The Journal of Immunology*, 201(11), pp.3362-3372. DOI: 10.4049/jimmunol.1701582.
- 59.** Michaux, C., Ronneau, S., Giorgio, R.T. and Helaine, S.,(2022). Antibiotic tolerance and persistence have distinct fitness trade-offs. *PLoS pathogens*, 18(11), p.e1010963. <https://doi.org/10.1371/journal.ppat.1010963>.
- 60.** Balaban, N.Q., Helaine, S., Lewis, K., Ackermann, M., Aldridge, B., Andersson, D.I., Brynildsen, M.P., Bumann, D., Camilli, A., Collins, J.J. and Dehio, C., (2019). Definitions and guidelines for research on antibiotic persistence. *Nature Reviews Microbiology*, 17(7), pp. 441-448. <https://doi.org/10.1038/s41579-019-0196-3>.
- 61.** Równicki, M., Pieńko, T., Czarnecki, J., Kolanowska, M., Bartosik, D. and Trylska, J., (2018). Artificial activation of *Escherichia coli* mazEF and hipBA toxin-antitoxin systems by antisense peptide nucleic acids as an antibacterial strategy. *Frontiers in microbiology*, 9, p. 2870. : <https://doi.org/10.3389/fmicb.2018.02870>.
- 62.** Kurup, S.P., Obeng-Adjei, N., Anthony, S.M., Traore, B., Doumbo, O.K., Butler, N.S., Crompton, P.D. and Harty, J.T., (2017). Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. *Nature medicine*, 23(10), pp.1220-1225. DOI: **10.1038/nm.4395**.

- 63.** Joosten, S.A., van Meijgaarden, K.E., van Weeren, P.C., Kazi, F., Geluk, A., Savage, N.D., Drijfhout, J.W., Flower, D.R., Hanekom, W.A., Klein, M.R. and Ottenhoff, T.H., (2010). Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8+ T-cells with cytotoxic as well as regulatory activity. *PLoS pathogens*, 6(2), p.e1000782. DOI: **10.1371/journal.ppat.100078**.
- 64.** Li, S., Vriend, L.E., Nasser, I.A., Popov, Y., Afdhal, N.H., Koziel, M.J., Schuppan, D., Exley, M.A. and Alatrakchi, N., (2012). Hepatitis c virus-specific t-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis. *Hepatology*, 56(6), pp.2094-2105. DOI: **10.1002/hep.25951**.
- 65.** Fogg, M., Murphy, J.R., Lorch, J., Posner, M. and Wang, F., (2013). Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein–Barr virus associated nasopharyngeal carcinoma. *Virology*, 441(2), pp.107-113. DOI: **10.1016/j.virol.2013.03.016**.
- 66.** Redford, P.S., Boonstra, A., Read, S., Pitt, J., Graham, C., Stavropoulos, E., Bancroft, G.J. and O'Garra, A., (2010). Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. *European journal of immunology*, 40(8), pp.2200-2210. DOI: 10.1002/eji.201040433.
- 67.** Tang-Feldman, Y.J., Lochhead, G.R., Lochhead, S.R., Yu, C. & Pomeroy, C. (2011) 'Interleukin-10 repletion suppresses proinflammatory cytokines and decreases liver pathology without altering viral replication in murine cytomegalovirus (MCMV)-infected IL-10 knockout mice', *Inflammation Research*, 60(3), pp.233–243. DOI: 10.1007/s00011-010-0259-4.
- 68.** Windish, H.P., Lin, P.L., Mattila, J.T. et al. (2009) 'Aberrant TGF- β signaling reduces T regulatory cells in ICAM-1-deficient mice, increasing the inflammatory response to Mycobacterium tuberculosis', *Journal of Leukocyte Biology*, 86(3), pp.713–725. DOI: 10.1189/jlb.1208740 .
- 69.** Khamees, H. H., Mohammed, A. A., Hussein, S. A. M., Ahmed, M. A. & Raouf, A. S. M. (2024). In-silico study of destabilizing Alzheimer's A β 242 protofibrils with curcumin. *International Journal of Medical Science and Dental Health*, 10(5), pp.76–84. <https://doi.org/10.55640/ijmsdh-10-05-07>.

70. Gunn, J.S., Lim, K.B., Krueger, J., Kim, K., Guo, L., Hackett, M. & Miller, S.I., (1998). PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. *Molecular Microbiology*, 27(6), pp.1171–1182. <https://doi.org/10.1046/j.1365-2958.1998.00757>.
71. Lebeaux, D., Ghigo, J.M. & Beloin, C., (2014). Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. *Microbiology and Molecular Biology Reviews*, 78(3), pp.510–543. <https://doi.org/10.1128/MMBR.00013-14>.
72. Brandao, A.P.M., Oliveira, F.S., Carvalho, N.B., Vieira, L.Q., Azevedo, V., Macedo, G.C. & Oliveira, S.C., (2012). Host susceptibility to *Brucella abortus* infection is more pronounced in IFN- γ knockout than IL-12/ β 2-microglobulin double-deficient mice. *Journal of Immunology Research*, (2012) (1), p.589494. DOI: 10.1155/2012/589494.
73. Nogueira, C.V., Zhang, X., Giovannone, N., Sennott, E.L. & Starnbach, M.N., (2015). Protective immunity against *Chlamydia trachomatis* can engage both CD4+ and CD8+ T cells and bridge the respiratory and genital mucosae. *The Journal of Immunology*, 194(5), pp.2319–2329. DOI: 10.4049/jimmunol.1402675.